FY2025 EPS Forecast for TG Therapeutics Increased by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for shares of TG Therapeutics in a report released on Tuesday, March 4th. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will post earnings of $1.39 per share for the year, up from their prior estimate of $1.26. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2026 earnings at $2.27 EPS and FY2027 earnings at $2.86 EPS.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

Several other equities research analysts also recently commented on the company. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Price Performance

TGTX stock opened at $35.62 on Wednesday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market capitalization of $5.54 billion, a price-to-earnings ratio of -356.16 and a beta of 2.30. The firm has a 50 day moving average price of $30.86 and a 200-day moving average price of $28.33. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $36.94.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Vermillion Wealth Management Inc. bought a new position in TG Therapeutics in the 4th quarter worth $30,000. Quadrant Capital Group LLC raised its stake in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 975 shares during the period. Blue Trust Inc. raised its stake in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 371 shares during the period. Smartleaf Asset Management LLC lifted its holdings in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,594 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,737 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.